Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 5:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Insulin Human Injection Clear all
Completed Not applicable Interventional

Automated Insulin Delivery (AID) for Basal Insulin Titration in Type 2 Diabetes

NCT06024928
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Control-IQ use in Type 2 Diabetes under basal insulin injections
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)

NCT00916357
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency

NCT00125164
View directory record Official record
Conditions
Growth Disorders, Insulin-Like Growth Factor-1 Deficiency
Interventions
rhIGF-1 (mecasermin, Tercica, Inc.)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
3 Years to 12 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Glycemic Control and Variability for Congestive Heart Failure Exacerbation

NCT00812487
View directory record Official record
Conditions
Congestive Heart Failure, Diabetes Mellitus
Interventions
Intravenous insulin, Subcutaneous insulin
Drug
Lead sponsor
Kathleen Dungan
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 30, 2013 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes

NCT00605475
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Canakinumab, Placebo, Metformin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
6
States / cities
Little Rock, Arkansas • Miami, Florida • MD, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2012 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Not applicable Interventional Results available

IV Insulin Protocol in Diabetes and Renal Transplantation

NCT00609986
View directory record Official record
Conditions
Kidney Transplantation, Diabetes, Hyperglycemia
Interventions
insulin, NPH Insulin or glargine insulin and aspartame insulin
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes

NCT02660242
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
G-Pen Mini™ (glucagon injection), Glucose Tabs, Basal Insulin Reduction
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Phase 1 Interventional

Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes

NCT01334151
View directory record Official record
Conditions
Diabetes Mellitus Type 1
Interventions
Insulin LISPRO, recombinant human insulin
Drug
Lead sponsor
Biodel
Industry
Eligibility
19 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2013 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)

NCT00641056
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide Once Weekly, Insulin Glargine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Escondido, California • Jacksonville, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2015 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Exenatide in Patients With Diabetic Neuropathy

NCT00855439
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetic Peripheral Neuropathy
Interventions
Exenatide, Glargine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Phase 4 Interventional Results available

Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

NCT01526733
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sham Injection, Recombinant human hyaluronidase PH20, Insulin aspart, Insulin lispro
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Not applicable Interventional

Artificial Pancreas - Adolescent Physiology & Psychology Longitudinal Evaluation

NCT04510506
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Artificial Pancreas (AP)
Device
Lead sponsor
University of Virginia
Other
Eligibility
11 Years to 12 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin

NCT04770532
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin degludec, Insulin Icodec
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
38
States / cities
Buena Park, California • Encino, California • Fresno, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Not applicable Interventional Results available

Hyperglycemia in Renal Transplantation

NCT01643382
View directory record Official record
Conditions
Diabetes, End Stage Renal Disease
Interventions
Insulin, Insulin, Asp(B28)-
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Sep 18, 2026, 5:07 AM EDT
Active, not recruiting Phase 4 Interventional

Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia

NCT06986603
View directory record Official record
Conditions
Hypoglycemia, Hypoglycemia, Reactive, Bariatric Surgery
Interventions
Glucagon for Injection (Fresenius Kabi USA)
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Early Phase 1 Interventional Results available

Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents

NCT02726542
View directory record Official record
Conditions
NAFLD
Interventions
somatropin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 29 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

NCT03922750
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin glargine U100
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
13
States / cities
Walnut Creek, California • Roswell, Georgia • Idaho Falls, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes

NCT00612040
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
9
States / cities
Walnut Creek, California • Honolulu, Hawaii • Idaho Falls, Idaho + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 18, 2026, 5:07 AM EDT
Recruiting Not applicable Interventional

Hybrid Closed Loop Effectiveness Trial in Adults With Type 1 Diabetes

NCT06236607
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Complications
Interventions
Device specific training, Study clinician/educator visit
Device · Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 18, 2026, 5:07 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Prospective Randomized Double Blinded Controlled Trial of Non-Operative Management of TFCC Injuries

NCT03830775
View directory record Official record
Conditions
Wrist Injuries, PRP
Interventions
Platelet-rich plasma (PRP)
Procedure
Lead sponsor
Edna Rath
Federal
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Afrezza Safety and Pharmacokinetics Study in Pediatric Patients

NCT02527265
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Afrezza
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
4 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Phase 1 Interventional

Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab

NCT06272695
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Volagidemab
Biological
Lead sponsor
REMD Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 72 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
San Deigo, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

NCT05462756
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
Interventions
Insulin Efsitora Alfa, Insulin Lispro (U100), Insulin Glargine (U100)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
24
States / cities
Hamden, Connecticut • Clearwater, Florida • Miami Lakes, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Sep 18, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

NCT01476475
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine /lixisenatide Fixed Ratio Combination, Insulin glargine, Metformin (Background drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Little Rock, Arkansas • Paramount, California • Larenceville, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 18, 2026, 5:07 AM EDT